AbbVie’s Skyrizi has demonstrated significantly higher rates of steroid-free clinical and endoscopic remission versus rival Johnson & Johnson’s Stelara in a Phase III trial, helping set the Crohn’s disease drug apart in an increasingly competitive market.
Stelara won an FDA approval for Crohn’s disease in 2016, while Skyrizi was approved…
Click here to view original post
